FDA Grants Emergency Use Authorization for Kantaro’s Breakthrough COVID-19 Antibody Kit

Last Wednesday, November 25, The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for Kantaro’s COVID-SeroKlir antibody test kit for SARS-CoV-2, the virus that causes COVID-19. Unlike many other antibody tests on the market, Kantaro’s test detects both the presence and precise value of COVID-19 antibodies, rather than just a yes/no answer. By giving patients a clear antibody number, it allows patients to take charge of their health and can help businesses, governments and other organizations create data-driven policies to keep more people safe and help fight back against COVID-19.

As CNN reports, Kantaro’s antibody test can also help evaluate the effectiveness of vaccines as they come on the market. The test is now available in the U.S. and in 29 European countries.